Expanding on this a bit. Reading what everyo
Post# of 36537
Reading what everyone wrote, and I'm getting off the IPO a minute, one thing this CC apparently showed is that Generex / NGIO is now not a one trick pony.
While they have been working on the vaccine, they now have:
Excellagen
Florida deals
Arizona deals
Cancer drug
Diabetes
and probably a few more.
So, they are pretty well rounded here. If you think about it, this company (s), while we can get frustrated at times, has been setting itself up to cover a lot of areas and to put itself in a place to succeed in the long run. Looks like on the call, they gave a good accounting on a lot of it.